Ursonic acid (Synonyms: 3-Ketoursolic acid)

Name: Ursonic acid
Brand: MedChemExpress
SKU: HY-N1486
Rating: 4.5 (1 reviews)

Cat. No.: HY-N1486 Purity: 98.15%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ursolic acid is a naturally occurring triterpenoid that has orally active. Ursolic acid induces the apoptosis of human cancer cells through multiple signaling pathways. Ursolic acid has anti-inflammatory and anticarcinogenic activity.

For research use only. We do not sell to patients.

Ursonic acid Chemical Structure

CAS No. : 6246-46-4

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 80	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 110	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 165	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Ursonic acid

•Pharmacol Res. 2024 May 9:204:107208. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 50 μM Compound: 7a	Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
A549	IC₅₀	15 μM Compound: 2	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26854375]
A549	GI₅₀	57 μM Compound: 16	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
ASPC1	IC₅₀	24.5 μM Compound: 4	Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay	[PMID: 22959527]
BJ	IC₅₀	> 50 μM Compound: 7a	Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
CCRF-CEM	IC₅₀	10.4 μM Compound: 7a	Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
HCT-116	IC₅₀	> 50 μM Compound: 7a	Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
HCT-116	IC₅₀	2.3 μM Compound: 2	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26854375]
HCT-116	IC₅₀	49.7 μM Compound: 7a	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
HCT-116	GI₅₀	5.3 μM Compound: 16	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
HeLa	IC₅₀	> 40 μM Compound: 2	Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28733083]
HepG2	IC₅₀	> 100 μM Compound: 2	Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25537271]
HepG2	CC₅₀	> 400 μM Compound: 4a	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29326018]
HL-60	IC₅₀	> 40 μM Compound: 2	Growth inhibition of human HL60 cells after 48 hrs by MTT assay Growth inhibition of human HL60 cells after 48 hrs by MTT assay	[PMID: 28073673]
K562	IC₅₀	> 50 μM Compound: 7a	Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
MCF7	GI₅₀	12 μM Compound: 16	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32345458]
MCF7	IC₅₀	56 μM Compound: 2	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26854375]
MDA-MB-231	IC₅₀	> 40 μM Compound: 2	Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28733083]
MRC5	IC₅₀	> 50 μM Compound: 7a	Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
NTUB1	IC₅₀	21.44 μM Compound: 18	Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay	[PMID: 19758808]
RAW264.7	IC₅₀	4.94 μM Compound: 2	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 28427811]
SMMC-7721	IC₅₀	> 40 μM Compound: 2	Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 28733083]
THP-1	IC₅₀	13 μM Compound: 2	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 26854375]
U2OS	IC₅₀	> 50 μM Compound: 7a	Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
Vero	CC₅₀	> 400 μM Compound: 4a	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 29326018]
Vero	IC₅₀	2.5 μg/mL Compound: 5, ursonic acid	Antiviral activity against HSV1 MacIntyre replication in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against HSV1 MacIntyre replication in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 2828553]
Vero	IC₅₀	8 μg/mL Compound: 5, ursonic acid	Antiviral activity against HSV2 MS replication infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against HSV2 MS replication infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 2828553]

In Vitro

Ursolic acid (12.5-50 μM, 48 h) induce apoptosis in T24 human bladder cancer cells in a dose-dependent manner by inhibiting AKT/NF-κB signaling^[1].
Ursolic acid (50 μM, 2-4 h) increases the expression of p53 and caspase-3 and decreases bcl-2 gene expression in B16F-10 melanoma cells^[2].
Ursolic acid (10-50 μM, 48 h) inhibits the production of TNF-α, IL-1β, IL-6 and GM-CSF in B16F-10 melanoma cells^[2].
Ursolic acid (50 μM, 2 h) inhibits the NF-κB subunits (p65, p50 and c-Rel) and nuclear translocation of c-fos, ATF-2 and CREB-1 in B16F-10 melanoma cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	T24 human bladder cancer cells
Concentration:	12.5-50 μM
Incubation Time:	48 h
Result:	Inhibited cell proliferation in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:	T24 human bladder cancer cells
Concentration:	12.5-50 μM
Incubation Time:	48 h
Result:	Inhibited the anti-apoptotic signaling (pAkt1, pIκBα, NF-κBp65 and Bcl-2). Activated pro-apoptotic signaling (caspase-3).

In Vivo

Ursolic acid (5-20 mg/kg, p.o., twice a day, 30 days) protects against ethanol-mediated experimental liver injury in adult male albino rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male albino rats^[3]
Dosage:	5-20 mg/kg
Administration:	p.o., twice a day, 30 days
Result:	Increased weight gain and food intake. Decreased AST and ALT activities and total and indirect bilirubin levels. Increased direct bilirubin and levels of non-enzymic antioxidants (GSH, ascorbic acid and a-tocopherol). Decreased lipid peroxidation.

Molecular Weight

454.68

Formula

C₃₀H₄₆O₃

CAS No.

6246-46-4

Appearance

Solid

Color

White to off-white

SMILES

CC1(C)C(CC[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H])=O

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (109.97 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1993 mL	10.9967 mL	21.9935 mL
5 mM	0.4399 mL	2.1993 mL	4.3987 mL
10 mM	0.2199 mL	1.0997 mL	2.1993 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.15%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (251 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. Gai, L., Cai, N., Wang, L., Xu, X. & Kong, X. Ursolic acid induces apoptosis via Akt/NF-kappaB signaling suppression in T24 human bladder cancer cells. Molecular medicine reports 7, 1673-1677, doi:10.3892/mmr.2013.1364 (2013). [Content Brief]

[2]. Manu, K. A. & Kuttan, G. Ursolic acid induces apoptosis by activating p53 and caspase-3 gene expressions and suppressing NF-kappaB mediated activation of bcl-2 in B16F-10 melanoma cells. International immunopharmacology 8, 974-981, doi:10.1016/j.intimp.2008.02.013 (2008). [Content Brief]

[3]. Saravanan R, et al. Protective effect of ursolic acid on ethanol-mediated experimental liver damage in rats. Life Sci. 2006 Jan 11;78(7):713-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1993 mL	10.9967 mL	21.9935 mL	54.9837 mL
	5 mM	0.4399 mL	2.1993 mL	4.3987 mL	10.9967 mL
	10 mM	0.2199 mL	1.0997 mL	2.1993 mL	5.4984 mL
	15 mM	0.1466 mL	0.7331 mL	1.4662 mL	3.6656 mL
	20 mM	0.1100 mL	0.5498 mL	1.0997 mL	2.7492 mL
	25 mM	0.0880 mL	0.4399 mL	0.8797 mL	2.1993 mL
	30 mM	0.0733 mL	0.3666 mL	0.7331 mL	1.8328 mL
	40 mM	0.0550 mL	0.2749 mL	0.5498 mL	1.3746 mL
	50 mM	0.0440 mL	0.2199 mL	0.4399 mL	1.0997 mL
	60 mM	0.0367 mL	0.1833 mL	0.3666 mL	0.9164 mL
	80 mM	0.0275 mL	0.1375 mL	0.2749 mL	0.6873 mL
	100 mM	0.0220 mL	0.1100 mL	0.2199 mL	0.5498 mL

Ursonic acid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Ursonic acid (Synonyms: 3-Ketoursolic acid)

Customer Review

1 Publications Citing Use of MCE Ursonic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ursonic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ursonic acid (Synonyms: 3-Ketoursolic acid)

Customer Review

Ursonic acid Related Antibodies

1 Publications Citing Use of MCE Ursonic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Ursonic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ursonic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report